Skip to content
Company Analysis

Pacific Biosciences of Californ PACB

A comprehensive view of key metrics, scores, and financial health for Pacific Biosciences of Californ

Overview of Pacific Biosciences of California, Inc.

PACB NMS
Healthcare Medical Devices Small Cap
Pacific Biosciences of California, Inc. (PACB), is a Small Cap company, in the Medical Devices industry, last closed at $1.33, about 0.0% overvalued vs fair value, +7.3% 1Y return, ranked 720/1110 in sector.
$1.33
4.72%
As of March 13, 2026
Previous close • Vol 90d: 94.3%
52-Week Range
Market Cap
$416.80M
Enterprise Value
$896.76M
Overall Score
Scores locked

Create a free account to see overall and pillar scores for Pacific Biosciences of Californ.

Top Beats

Quick Facts

Website https://www.pacb.com
HQ Menlo Park, CA
Employees 485
Fiscal year Dec 31

Next Events

No upcoming events available.

Fair Value Snapshot

Bear Base Bull
$-2
$-2
$-2
Current: $1.33

Engine Room Money Flow™

Small Cap

Corporate Free Cash Flow - Where revenue goes and how value is created

Flow Steps
Revenue
$160.0M
3.9%%
Gross Profit
$50.7M
35.9%%
Operating Income
$-557.6M
-91.8%%
Net Income
$-546.4M
-76.3%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Corporate Free Cash Flow

Quality & Reliability Indicators

Cash Conversion Ratio
38.8%
Poor

FCF / Net Income - measures how well earnings convert to cash

Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
2
Active Leaks
0/2
Improving
0
High Impact
2
Critical
Locked Leak
Upgrade to view details
Premium
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Pacific Biosciences of Californ's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
32
/100
Developing
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Weak
23
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Generic Industrial / Default vs Industry Peers 88% Coverage
Trade-Off Triangle Visualization A ternary plot showing PACB's balance between Growth (33.7%), Profitability (27.4%), and Safety (38.9%). Growth 34% Safety 39% Profitability 27%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

40th percentile vs peers
41
Key Signals
Rev Growth YoY 3.9% 41p Revenue CAGR 3Y 7.6% 42p EPS Growth YoY 11.2% 36p
Strengths
  • D/E Ratio in top 20% of peers (141.98, 99th percentile)
  • Current Ratio in top 20% of peers (6.89, 82th percentile)
  • Quick Ratio in top 20% of peers (5.99, 84th percentile)
  • Strong liquidity position vs peers
  • Conservative leverage compared to industry peers
Risks
  • Growth below peer median (percentile: 40)

Profitability

33th percentile vs peers
33
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

46th percentile vs peers
47
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Pacific Biosciences of Californ.

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$-1.73
- - -
- upside
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info